Q3 2020 Sales Performance

Redefining HIV PrEP with long-acting cabotegravir Cabotegravir for PrEP Long acting, injectable cabotegravir administered every two months is 66% more effective than daily pills Working with the FDA and other regulatory agencies to prepare a file HPTN 083 an HIV prevention clinical trial Anticipated submission 1H 2021 Cl, confidence interval Source: Landovitz RJ et al. AIDS 2020, #OAXLB01 HIV Incidence Rate/100 PY 1.8 8 6 4 2 1.6 1.4 HIV Incidence Hazard Ratio (95% CI) 0.34 39 Infections 1.22 1.2 0.18 0.62 1 0.8 13 Infections 0.6 T 0.41 0.4 0.2 3202 PY 3187 PY 0 CAB n=2244 TDF/FTC n=2250 gsk 31 31

View entire presentation